#294 - Cholesterol Science Explained: Why Your LDL Score Doesn’t Tell the Whole Story | Dr. Ronald Krauss + Mike Haney
LEVELS – A Whole New LevelShow Notes
High cholesterol is one of the most widely discussed—and established—risk factors in medicine. But reams of research now show that while it is key to cardiovascular risk, it is not the whole story.
In this episode of A Whole New Level, editorial director Mike Haney sits down with Dr. Ronald Krauss, one of the world’s leading lipid researchers and a pioneer in understanding how different forms of LDL—and the physiological factors around them—affect cardiovascular risk.
Dr. Krauss explains why the basic link between cholesterol and heart disease is well established among experts—but also why the standard cholesterol panel often misses the deeper metabolic story. Drawing on decades of research, he walks through how lipoproteins, particle size, triglycerides, and metabolic health interact to determine whether cholesterol actually becomes dangerous.
Along the way, the conversation explores why cardiovascular disease remains the leading killer despite statins and decades of research—and how factors like obesity, insulin resistance, and inflammation reshape the lipid landscape in ways that traditional tests may not capture.
The result is a clearer framework for understanding cardiovascular risk: not just how much cholesterol is in the blood, but how it’s being transported, how long those particles circulate, and what metabolic conditions are driving them.
Sign Up to Get Your Free Ultimate Guide to Glucose: https://levels.link/wnl
In this episode, we cover Why the cholesterol–heart disease link isn’t actually controversial among researchers Cholesterol vs. lipoproteins: why the particles carrying cholesterol matter more than the number itself Small dense LDL: how triglyceride metabolism produces the most harmful particles ApoB and particle counts: why many researchers prefer measuring particles instead of cholesterol mass Lipoprotein(a): the genetically driven risk factor affecting up to a third of the population Metabolic syndrome: the cluster of conditions that amplifies cardiovascular risk Why carbohydrates and metabolic dysfunction can drive harmful lipid patterns The saturated fat debate: why food context and metabolic health matter more than simple fat categories
🎙 What Dr. Ronald Krauss & Mike Haney discuss: [01:09] — Why the cholesterol–heart disease link is largely settled science [02:27] — Why cardiovascular disease remains the world’s leading killer [04:42] — Inflammation and metabolic dysfunction in vascular disease [06:12] — The discovery of small dense LDL and why particle size matters [07:14] — Lipoprotein(a) as a major inherited cardiovascular risk factor [09:18] — “Residence time”: why particles that circulate longer cause more damage [11:24] — ApoB vs LDL-C: measuring particles instead of cholesterol mass [13:31] — The HDL paradox: why raising HDL hasn’t improved outcomes [15:28] — Metabolic syndrome and the five markers that amplify risk [17:16] — Why the saturated fat debate misses the bigger metabolic picture
Levels helps you see how food affects your health, empowering you with the tools needed to achieve health goals and improve healthspan. Levels Members gain access to the Levels app and continuous glucose monitors (CGMs), providing real-time feedback on how diet and lifestyle choices impact your metabolic health.
Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.
🔗 Helpful links Watch the conversation: https://youtu.be/sS0orvd2TFs Find us on YouTube: https://youtube.com/levelshealth?sub_confirmation=1
📲 Connect Connect with Dr. Ronald Krauss on LinkedIn: https://www.linkedin.com/in/ronald-krauss-81a38021/
More from LEVELS – A Whole New Level
Heart disease is the leading cause of death, but it’s also one of the most preventable. Decades of research have established a strong causal role for LDL and other ApoB-containing particles in atherosclerosis, and we now have multiple proven ways to lower them. The harder question is how to turn that evidence into a decision for an individual person. Mike Haney talks with Johns Hopkins cardiologist Dr. Seth Martin, a co-author of the new 2026 dyslipidemia guidelines, about what the latest evidence says we should actually measure and act on. The throughline is pragmatic: lower exposure to atherogenic particles earlier and for longer, use additional tests when they can change a decision, and distinguish interesting new measurements from ones that have actually been shown to improve outcomes.
Most of NextLevel starts with a measurement problem: we can see more biology than ever, but we still have to figure out what to do with it. Bioelectronic medicine flips that sequence. We already know how to send electrical signals into the nervous system to change biology, including an FDA-approved vagus nerve treatment for rheumatoid arthritis, even though we still can’t map or read most of the individual nerve fibers carrying those signals.
Most health decisions happen before the science is settled. A study points one way, another points somewhere else, experts disagree about what matters, and even strong population-level evidence may not tell you what will happen to you.
Most medical imaging happens after a symptom, injury, or abnormal test gives a clinician a reason to look. But what changes if imaging becomes a more routine measurement, creating a record of the body before something goes wrong? In this episode of Next Level, Mike Haney talks with Dr. Daniel Durand, chief medical officer at Prenuvo, about whole-body MRI as a test case for a broader shift from episodic medicine toward longitudinal health data. Whole-body MRI is controversial, and Durand is clearly an advocate. The conversation takes the skepticism seriously, then asks a larger question: as measurement gets cheaper, more frequent, and increasingly visible to patients themselves, how should medicine decide what is worth knowing?
Alcohol has spent the last 40 years bouncing between two health narratives: a little is good for your heart, or any amount is dangerous. The science doesn’t really support either slogan. Dr. Tim Naimi has spent decades studying the health effects of alcohol and, just as importantly, why the research is so difficult to interpret. His read of the evidence is less dramatic but more useful: there’s no good reason to start drinking for your health, very low intake may carry little measurable added risk, and risk rises as consumption does. Understanding why earlier studies made moderate drinking look protective helps explain a lot of the whiplashing headlines.